| No PPM (n = 165) (45.7%) | PPM (n = 196) (54.3%) | p Value | |
| Age (years) | 65.4 (11.3) | 72.9 (7.7) | <0.0001 |
| Female | 67 (40.6%) | 123 (62.8%) | <0.0001 |
| EuroSCORE | 5.6 (2.6) | 6.9 (2.2) | <0.0001 |
| Body surface area (m2) | 1.84 (0.2) | 1.91 (0.2) | 0.003 |
| Body mass index (kg/m2) | 25.9 (4.1) | 28.5 (4.4) | <0.0001 |
| Previous cardiac surgery | 10 (6.1%) | 15 (7.7%) | 0.55 |
| Previous valve surgery | 9 (5.5%) | 5 (2.6%) | 0.16 |
| Coronary artery disease | 50 (30.3%) | 86 (43.9%) | 0.038 |
| Triple vessel disease | 7 (4.2%) | 20 (10.2%) | 0.031 |
| LVEF 30–50% | 25 (15.2%) | 11 (5.6%) | 0.003 |
| Hypertension | 102 (61.8%) | 145 (74.0%) | 0.013 |
| Diabetes | 26 (15.8%) | 42 (21.4%) | 0.17 |
| Hypercholesterolaemia | 85 (51.5%) | 93 (47.5%) | 0.44 |
| COPD | 11 (6.7%) | 23 (11.7%) | 0.10 |
| Creatinine | 1.08 (0.3) | 1.15 (0.7) | 0.23 |
| Renal failure | 7 (4.2%) | 2 (1.0%) | 0.13 |
| Artheriopathy | 28 (17.0%) | 33 (16.8%) | 0.97 |
| NYHA | 2.19 (0.71) | 2.42 (0.66 | 0.001 |
| NYHA ⩾III | 37 (22.4%) | 71 (36.2%) | 0.004 |
| CCS | 1.58 (0.70) | 1.66 (0.75) | 0.66 |
| LVOT diameter (mm) | 20.9 (2.5) | 19.8 (2.2) | 0.001 |
| Aortic valve EOA (cm2) | 0.62 (0.17) | 0.61 (0.18) | 0.43 |
| Aortic valve EOAi (cm2/m2) | 0.29 (0.14) | 0.31 (0.11) | 0.06 |
| Mean aortic valve gradient (mm Hg) | 64.4 (21.2) | 66.6 (18.0) | 0.29 |
| Peak velocity (m/s) | 4.9 (0.9) | 5.0 (0.7) | 0.24 |
Values are expressed as mean (SD) or number (%).
PPM, patient-prosthesis mismatch; LVEF indicates left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; LVOT, left ventricular outflow tract; EOA, effective orifice area; EOAi, indexed effective orifice area.